Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK Gene Mutation”

62 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 62 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05491811
What this trial is testing

Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation

Who this might be right for
Non-Small Cell Lung Cancer
Sun Yat-sen University 49
Testing effectiveness (Phase 2)Looking for participantsNCT06947694
What this trial is testing

A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases

Who this might be right for
NSCLC Stage IV Without EGFR/ALK Mutation
Xinqiao Hospital of Chongqing 427
Not applicableActive Not RecruitingNCT05370469
What this trial is testing

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

Who this might be right for
Lung CancerEGFR Gene MutationEGFR+6 more
University of Virginia 30
Not applicableUnknownNCT04921553
What this trial is testing

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

Who this might be right for
CancerCancer MetastaticNTRK Gene Fusion Overexpression+13 more
Centre Leon Berard 500
Post-approval studies (Phase 4)Looking for participantsNCT05525338
What this trial is testing

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels

Who this might be right for
Drug MonitoringCarcinoma, Non-Small-Cell LungLung Cancer+2 more
University Medical Center Groningen 196
Testing effectiveness (Phase 2)Study completedNCT03049618
What this trial is testing

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Who this might be right for
ALK Gene MutationBRAF Gene MutationEGFR Gene Mutation+9 more
University of Southern California 42
Early research (Phase 1)Study completedNCT01531361
What this trial is testing

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Who this might be right for
Advanced Malignant NeoplasmBRAF Gene MutationMetastatic Malignant Neoplasm+2 more
M.D. Anderson Cancer Center 46
Large-scale testing (Phase 3)Looking for participantsNCT05722886
What this trial is testing

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Who this might be right for
Haematological MalignancySolid Tumour
Cancer Research UK 825
Testing effectiveness (Phase 2)Active Not RecruitingNCT05200481
What this trial is testing

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Who this might be right for
Non Small Cell Lung CancerALK Gene Mutation
Intergroupe Francophone de Cancerologie Thoracique 110
Not applicableLooking for participantsNCT03042221
What this trial is testing

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

Who this might be right for
Non-Small Cell Carcinoma of Lung, TNM Stage 4Non-Small Cell Lung CancerEGFR Gene Mutation+3 more
University of Colorado, Denver 100
Not applicableNot Yet RecruitingNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Large-scale testing (Phase 3)Not Yet RecruitingNCT04772287
What this trial is testing

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 341
Testing effectiveness (Phase 2)Looking for participantsNCT05351320
What this trial is testing

WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Jinming Yu 40
Testing effectiveness (Phase 2)WithdrawnNCT03868423
What this trial is testing

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

Who this might be right for
Advanced Malignant NeoplasmALK Fusion Protein ExpressionALK Gene Amplification+8 more
Sameek Roychowdhury
Not applicableStudy completedNCT02010047
What this trial is testing

Comparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC Patients

Who this might be right for
Nonsmall Cell Lung Cancer
British Columbia Cancer Agency 166
Testing effectiveness (Phase 2)UnknownNCT03654027
What this trial is testing

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

Who this might be right for
Non-small Cell Lung Cancer
First Affiliated Hospital of Guangxi Medical University 84
Large-scale testing (Phase 3)Looking for participantsNCT05236946
What this trial is testing

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT

Who this might be right for
Asymptomatic Brain MetastasesDriver Mutation Positive Non-small Cell Lung Cancer
Tata Memorial Hospital 190
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06951399
What this trial is testing

Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC Stage IV Without EGFR/ALK MutationNSCLC Adenocarcinoma
Rabin Medical Center 30
Testing effectiveness (Phase 2)UnknownNCT04989322
What this trial is testing

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Who this might be right for
NsclcEGFR Activating MutationEGF-R Positive Non-Small Cell Lung Cancer+3 more
Dr Joanne CHIU 46
Testing effectiveness (Phase 2)Ended earlyNCT02846792
What this trial is testing

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Who this might be right for
ALK Gene TranslocationEGFR Activating MutationRecurrent Non-Small Cell Lung Carcinoma+3 more
University of Washington 5
Load More Results